|Bid||4.41 x 1100|
|Ask||4.42 x 800|
|Day's Range||4.40 - 4.52|
|52 Week Range||3.30 - 8.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.15|
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
NEW YORK, July 06, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All Persons or Entities who purchased Keryx Biopharmaceuticals, Inc. stock prior to June 28, 2018. You are ...
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
NEW YORK, July 02, 2018-- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Keryx Biopharmaceuticals, Inc. stockholders concerning the proposed acquisition of the company by Akebia ...
NEW YORK , June 29, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc. ("KERX" ...
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Shares of both companies tumble after the two entities announced the signing of a merger agreement. Here's what investors need to know.
The companies are to form a new, fully integrated company focused on chronic kidney diseases (or CKD) called Akebia Therapeutics. If Keryx Biopharmaceuticals manages to completely convert its outstanding convertible notes, the pro forma equity value of the combined company would be $1.3 billion, based on the closing share prices of the companies yesterday. Keryx is to add Auryxia, a drug approved by the FDA for hyperphosphatemia in CKD patients dependent on dialysis and for iron deficiency anemia in CKD patients not dependent on dialysis, to Akebia Therapeutics’ product portfolio.
Akebia Therapeutics, Inc. (AKBA) and Keryx Biopharmaceuticals, Inc. (KERX) today announced that the companies signed, and the boards of directors of both companies have unanimously approved, a definitive merger agreement under which the companies will combine in an all-stock merger. The transaction will create a fully integrated biopharmaceutical company focused on chronic kidney disease (CKD), with an implied pro forma equity value of approximately $1.3 billion, assuming full conversion of Keryx’s outstanding convertible notes, based on the closing prices of Keryx and Akebia on June 27, 2018. The combined company will be named Akebia Therapeutics, Inc.
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced participating in an upcoming panel in New York City. The JMP Securities Life Sciences Conference on Thursday, June 21st at 11:00 a.m. Eastern time: Keryx will be participating in a 50 minute panel discussion titled Renal Disease: Recent Advancements and Future Prospects at The St. Regis New York Hotel in New York City. A live audio webcast of the panel discussion will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “events and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the panel discussion.
Keryx (KERX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Keryx Biopharma, Inc. (NASDAQ: KERX) ("Keryx"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KERX as the Company's latest news hit the wire. On May 25, 2018, the Company shared the data from an investigator sponsored clinical trial that showed the impact of the use of ferric citrate in treating patients with advanced chronic kidney disease (CKD). The Company presented the results at the recently-held 55th ERA-EDTA Congress held at Copenhagen, Denmark, from May 24, 2018, to May 27, 2018.
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced two upcoming investor presentations in New York City. Key Opinion Leader Presentation on Iron Deficiency Anemia in Patients w/Chronic Kidney Disease on Thursday, May 31st at noon Eastern time: The event will feature a presentation by Glenn Chertow, MD, MPH, Professor of Medicine and Chief, Division of Nephrology at Stanford University School of Medicine. Jefferies Global Healthcare Conference Presentation on Wednesday, June 6th at 3:00 p.m. Eastern time: The Company will be providing a corporate update at the Jefferies Global Healthcare Conference, taking place June 5-8 at the Grand Hyatt Hotel in New York City.
When Keryx Biopharmaceuticals Inc’s (NASDAQ:KERX) announced its latest earnings (31 March 2018), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I usedRead More...
Keryx Biopharmaceuticals, Inc. (KERX), a company focused on bringing innovative medicines to people with kidney disease, announced today that data from an investigator sponsored study that evaluated the use of ferric citrate in patients with advanced chronic kidney disease (CKD) was presented as a late-breaking oral presentation at the 55th annual ERA/EDTA congress in Copenhagen. The open-label, single-center study evaluated use of ferric citrate compared to standard of care treatment (SOC) in late-stage non-dialysis dependent CKD patients. Patients with eGFR
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Keryx Biopharmaceuticals Inc’s (NASDAQ:KERX): Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. On 31 December 2017, theRead More...
The Boston-based company said it had a loss of 18 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the first quarter ended March 31, 2018. The company also reviewed its commercial progress with Auryxia and provided a general business update. “I am excited to be serving as the interim CEO of Keryx – we are in the midst of the launch of Auryxia for the treatment of iron deficiency anemia in people living with CKD and are seeing early indicators of traction,” said Jodie Morrison, interim chief executive officer of Keryx Biopharmaceuticals.
Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.
Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Thursday, May 10, 2018 at 8:00 a.m. ET to discuss its first quarter 2018 financial results and provide a business update. Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease.
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Gregory Madison has resigned as president and chief executive officer of the company and his seat on its board of directors, effective immediately. Jodie Morrison, a member of the company’s board of directors, has been named interim chief executive officer.